

Drug and Therapeutics Committee – Minutes

Date / Time	September 8 th 2022
Venue	WebEx
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Attendance	Prof A Morice, Chair, Professor of Respiratory Medicine Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Luke Storr – Senior Pharmacy Technician, Formulary HUTH Ms J Goode, Chief Pharmacist, HUTH Dr S Raise, GP Prescribing Lead, East Riding Prof M Lind, Vice Chair, Professor of Oncology, HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH
-------------------	--

Apologies	Mr P O'Brien, Deputy Chief Pharmacist, HUTH Dr H Klonin, Consultant Paediatrician, HUTH Prof T Sathyapalan, Consultant Endocrinologist, HUTH
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.10.01	Apologies	As Above.					
2022.10.02	Declarations of Interest	Prof. Lind Declared that he had been involved in several Pembrolizumab trials.					
2022.10.03	Minutes of the previous meeting	KMC raised issue about IBD audit completion to be on action tracker along with bluetech to be completed for new patients	Add to previous minutes and action tracker				
2022.10.04	Action Tracker	<p>Hydroxychloroquine in RA JM to discuss with relevant business managers- August 2022- to escalate to PE&CE JM has escalated and had no response back as of yet, JM to chase</p> <p>ARIA forms – Zoledronic acid JM to write trust guidance in conjunction with DME pharmacy team JM to extend due date as item is still going through governance</p> <p>NICE Guidance JM to meet with neurology about TA758.</p> <p>Clinical guidelines – Biologics and small molecules for IBD JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit JG to ensure new pharmacy service to IMIC is set up- JG to chase up if service was set up New action: Add guidance to agenda when updated- JM to meet Prof Sebastian, JM to chase</p> <p>NICE Guidance JM to check with Dr Gordins regarding TA769- JM has received no reply- JM to chase again and contact Dr Gupta</p> <p>MHRA Drug Safety Update April 2022 –Contact Mr Sedman about inclusion of pregabalin article in consultants newsletter</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p>	<p>Await response from PE&CE- JM to chase</p> <p>JM to meet Neurology</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>3/22</p> <p>1/23</p> <p>3/22</p> <p>9/22</p> <p>5/22</p> <p>7/22</p>	<p></p> <p></p> <p></p> <p></p> <p></p> <p>10/22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		Update: Aug 2022 – nothing in consultant newsletter JM to contact- Mr Sedman to include in upcoming newsletter					
		Any other business Check dermatology still require potassium permanganate- JM confirmed that still require potassium permanganate	Action complete		JM	7/22	10/22
		NICE guidance JM to contact Dr Jose and Dr Ming re TA808 (fenfluramine) September update: contacted Dr Ming and Dr Jose – JM to confirm NHSE requirements- Sheffield or Leeds are specialist and would supply currently have 1 patient. JM to see if Dr Ming wants to do an application	Ongoing		JM	9/22	
		NICE guidance JM to contact Dr Zaman and Emily Hardaker re TA803 (risankizumab for PA) to update dermatology guidance September update: JM contacted Emily Hardaker and will review guidance October update	Ongoing		JM	9/22	
		New product requests AM to write to applicants	Action complete		AM	10/22	
		New product requests LS to update formulary	Action Complete		LS	10/22	
		NICE Guidance JM to contact dermatology about TA814/TA815- JM awaiting reply	Ongoing		JM	10/22	
		NICE Guidance Update Sacituzimab to in line with NICE guidance on formulary- JM Updated	Ongoing		JM	10/22	
		NICE Guidance JM to contact ophthalmology about TA820- JM awaiting reply	Ongoing		JM	10/22	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		NICE Guidance To update back of formulary with TA814 and TA821- Updated Correspondence received To update formulary with andexenat alfa- Updated	Action complete Action complete		JM JM	10/22 10/22	10/22 10/22
2022.10.05	Tecovirimat- Monkey pox treatment	Requested application from Infectious diseases but no application as of yet. Agreed that if a request does come in before the application that it can be approved via chairs approval to ensure supply. Blueteq form for infectious diseases to complete which they have access to and are trained to use.	Request new product request form	Contact Dr Lillie	JM	11/22	
2022.10.06	New Product Requests	New Product Requests a) Somatogon (Ngenla)- (Dr Mathew) JM presented the evidence for this once weekly growth hormone. The use of the product was approved however; the number of products use was raised. AM to write to them and discuss the rationalisation of using fewer products b) Pembrolizumab (Dr Muazzam) – JM presented a free of charge scheme for this in renal cell carcinoma; this was approved due to unmet clinical need. This will be reviewed when the NICE TA is published. ARIA FORMS c) Abemaciclib & Letrozole – approved in line with NICE d) Alpelisib & Fulvestrant – approved in line with NICE	Approved- subject to rationalisation Approved Approved Approved	AM to write to applicants LS to update formulary	AM/L S	11/22	
2022.10.07	NICE guidance	Nice Guidance September 2022 <ul style="list-style-type: none"> NG225 Self-harm: assessment, management and preventing recurrence 	New guidance for prescribing and toxicity				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> TA822 Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) TA824 Dexamethasone intravitreal implant for treating diabetic macular oedema TA825 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis TA826 Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) NG122 Lung cancer: diagnosis and management CG189 Obesity: identification, assessment and management CG118 Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas TA823 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer TA829 Upadacitinib for treating active ankylosing spondylitis 	<p>Terminated appraisal- on formulary for other TA's</p> <p>On formulary for other TA</p> <p>New agent- requires NHSE vasculitis service</p> <p>Terminated appraisal</p> <p>Updated to add in TA, TA previously discussed</p> <p>Updated- nothing for D&T</p> <p>On formulary- ARIA form required</p> <p>On formulary- To add in line with TA</p>	JM contacted department if they require	JM	11/22	
2022.10.08	MHRA Drug safety update	<ul style="list-style-type: none"> September 2022 	Noted				
2022.10.09	Minutes of the Safe Medication Practice Committee	Nil this month	Complete	No action required			
2022.10.10	Minutes from the Hull and East Riding Prescribing Committee	a) August 2022 b) September 2022	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.10.11	Regional Medicines Optimisation Committee	Nil this month	Noted	No action required			
2022.10.12	Clinical guidelines	Nil this month	Noted	No action required			
2022.10.13	Correspondence received	<ul style="list-style-type: none"> Education case studies- JM had a meeting with company who provide Pattie re advertising of educational events. 	Not Approved	JM to respond	JM	11/22	
2022.10.14	Chairs Approvals	Nil this month		No action required			
2022.10.15	Issues to escalate to PE&CE	Nil this month					
2022.10.16	Any Other Business	<p>JM raised the point that she has an item not on the formulary with a TA, not received an application as different in NLaG etc. Discussion on if we still wish to continue our process of application, approval then brought to the commissioning.</p> <p>SR raised the point that there are a few diabetic drugs unavailable (semeglutide and dulaglutide).</p>	JM to put to next Humber APC	Add to agenda for next APC	LS	11/22	
2022.10.17	Date and Time of Next Meeting	10 th November 2022 8:15 am					